-
1 Comment
Zhangzhou Pientzehuang Pharmaceutical., Ltd is currently in a long term uptrend where the price is trading 45.9% above its 200 day moving average.
From a valuation standpoint, the stock is 200.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 28.9.
Zhangzhou Pientzehuang Pharmaceutical., Ltd's total revenue rose by 32.1% to $2B since the same quarter in the previous year.
Its net income has increased by 74.9% to $464M since the same quarter in the previous year.
Finally, its free cash flow grew by 146.0% to $937M since the same quarter in the previous year.
Based on the above factors, Zhangzhou Pientzehuang Pharmaceutical., Ltd gets an overall score of 4/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE000001F21 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | 124B |
|---|---|
| Target Price | 272.37 |
| Beta | 1.0 |
| PE Ratio | 40.22 |
| Dividend Yield | None |
Zhangzhou Pientzehuang Pharmaceutical., Ltd engages in the manufacture and sale of Chinese medicines under the Pien Tze Huang brand in China and internationally. Its products include Chinese herbal decoction pieces, health foods, beverages, medical equipment, tonics, Chinese herbal medicine slices, cosmetics, and daily chemical products. The company was founded in 1956 and is based in Zhangzhou, China. Zhangzhou Pientzehuang Pharmaceutical., Ltd is a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600436.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
